A registration certificate, issued by the Russian Ministry of Health, has been granted to Avineiro, a company within the ChemRar group. This certificate confirms the authorization of the drug Aviander to be used in the treatment of anxiety disorders. The drug was developed with the support of the Russian Ministry of Industry and Trade. All phases of the drug’s development, such as molecule synthesis, clinical trials, and production, were successfully completed in Russia.
The drug was able to quickly alleviate anxiety symptoms, as demonstrated by multicenter, randomized, placebo-controlled studies. Unlike traditional therapy, patients did not experience drowsiness or other side effects, ensuring better adherence to the prescribed treatment.
According to the company’s report, unlike other psychotropic drugs, this drug does not result in adverse reactions in the endocrine system, such as weight gain and sexual dysfunction.
